Neurobo Pharmaceuticals Stock Alpha and Beta Analysis
| NRBO Stock | USD 2.36 0.01 0.43% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neurobo Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neurobo Pharmaceuticals over a specified time horizon. Remember, high Neurobo Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neurobo Pharmaceuticals' market risk premium analysis include:
Beta 2.6 | Alpha (0.78) | Risk 4.85 | Sharpe Ratio (0.12) | Expected Return (0.60) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neurobo |
Neurobo Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neurobo Pharmaceuticals market risk premium is the additional return an investor will receive from holding Neurobo Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neurobo Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neurobo Pharmaceuticals' performance over market.| α | -0.78 | β | 2.60 |
Neurobo Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neurobo Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Neurobo Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neurobo Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Neurobo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurobo Pharmaceuticals shares will generate the highest return on investment. By understating and applying Neurobo Pharmaceuticals stock market price indicators, traders can identify Neurobo Pharmaceuticals position entry and exit signals to maximize returns.
Neurobo Pharmaceuticals Return and Market Media
The median price of Neurobo Pharmaceuticals for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 2.85 with a coefficient of variation of 15.35. The daily time series for the period is distributed with a sample standard deviation of 0.45, arithmetic mean of 2.95, and mean deviation of 0.39. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 407 shares by Dong-a St Co., Ltd of Neurobo Pharmaceuticals at 3.75 subject to Rule 16b-3 | 09/12/2024 |
2 | Acquisition by Dong-a St Co., Ltd of 2544530 shares of Neurobo Pharmaceuticals at 3.93 subject to Rule 16b-3 | 09/18/2024 |
3 | Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over 1,500 | 09/20/2024 |
4 | Insider Trading | 09/27/2024 |
5 | NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | 09/30/2024 |
6 | NRBO Positive SAD Part 1 Data MAD Part 2 Results Expected in 1Q25 | 10/01/2024 |
7 | NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH | 11/04/2024 |
8 | Acquisition by Strickland D Gordon of 12500 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 11/06/2024 |
9 | NRBO Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 | 11/13/2024 |
10 | NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Ca... | 11/18/2024 |
About Neurobo Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neurobo or other stocks. Alpha measures the amount that position in Neurobo Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Neurobo Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Neurobo Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neurobo Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neurobo Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neurobo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Neurobo Pharmaceuticals' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neurobo Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Neurobo Pharmaceuticals Backtesting, Neurobo Pharmaceuticals Valuation, Neurobo Pharmaceuticals Correlation, Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Volatility, Neurobo Pharmaceuticals History and analyze Neurobo Pharmaceuticals Performance. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Neurobo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.